Microencapsulated 3-piperidinyl-substituted...

Details Microencapsulated 3-piperidinyl-substituted... Microencapsulated 3-piperidinyl-substituted...

2006-10-10

2006-10-10

Richter, Johann (Department: 1626)

Drug, bio-affecting and body treating compositions

Preparations characterized by special physical form

Tablets, lozenges, or pills

C424S489000, C514S259410

Reexamination Certificate

active

07118763

ABSTRACT:
Sustained-release microparticle composition. The microparticle composition can be formulated to provide multi-phasic release. In one aspect, the composition includes microparticles having more than one rate of release. In another aspect, the composition includes microparticles that exhibit diffusional release and microparticles that exhibit biodegradation release.

REFERENCES:
patent: 3197180 (1965-07-01), Bates et al.
patent: 3523906 (1970-08-01), Vrancken et al.
patent: 3691090 (1972-09-01), Kitajima et al.
patent: 3737337 (1973-06-01), Schnoring et al.
patent: 3773919 (1973-11-01), Boswell et al.
patent: 3891570 (1975-06-01), Fukushima et al.
patent: 3960757 (1976-06-01), Morishita et al.
patent: 3923288 (1976-12-01), King et al.
patent: 4034965 (1977-07-01), King et al.
patent: 4111402 (1978-09-01), Barbini et al.
patent: 4128641 (1978-12-01), Itil
patent: 4201482 (1980-05-01), Imhauser et al.
patent: 4208136 (1980-06-01), King
patent: 4329331 (1982-05-01), Kallick
patent: 4335127 (1982-06-01), Vandenberk et al.
patent: 4337261 (1982-06-01), Shutske et al.
patent: 4342870 (1982-08-01), Kennis et al.
patent: 4352811 (1982-10-01), Strupczewski
patent: 4389330 (1983-06-01), Tice et al.
patent: 4443451 (1984-04-01), Kennis et al.
patent: 4458076 (1984-07-01), Strupczewski
patent: 4485107 (1984-11-01), Kennis et al.
patent: 4489055 (1984-12-01), Couvreur et al.
patent: 4511258 (1985-04-01), Federighi et al.
patent: 4529727 (1985-07-01), Kennis et al.
patent: 4530840 (1985-07-01), Tice et al.
patent: 4542025 (1985-09-01), Tice et al.
patent: 4585482 (1986-04-01), Tice et al.
patent: 4614440 (1986-09-01), King
patent: 4616937 (1986-10-01), King
patent: 4643584 (1987-02-01), Allocca
patent: 4665075 (1987-05-01), Vandenberk et al.
patent: 4675189 (1987-06-01), Kent et al.
patent: 4677191 (1987-06-01), Tankana et al.
patent: 4683288 (1987-07-01), Tankana et al.
patent: 4689330 (1987-08-01), Janssen et al.
patent: 4696258 (1987-09-01), Magrath et al.
patent: 4731205 (1988-03-01), McNulty
patent: 4737500 (1988-04-01), Sorg
patent: 4753535 (1988-06-01), King
patent: 4765204 (1988-08-01), Buchholz et al.
patent: 4793713 (1988-12-01), King et al.
patent: 4798786 (1989-01-01), Tice et al.
patent: 4804663 (1989-02-01), Kennis et al.
patent: 4808007 (1989-02-01), King et al.
patent: 4835139 (1989-05-01), Tice et al.
patent: 4883666 (1989-11-01), Sabel et al.
patent: 4897268 (1990-01-01), Tice et al.
patent: 4936689 (1990-06-01), Federighi et al.
patent: 4940588 (1990-07-01), Sparks et al.
patent: 4994281 (1991-02-01), Muranishi et al.
patent: 5008114 (1991-04-01), Lovrecich
patent: 5075109 (1991-12-01), Tice et al.
patent: 5102872 (1992-04-01), Singh et al.
patent: 5143661 (1992-09-01), Lawter et al.
patent: 5158952 (1992-10-01), Janssen et al.
patent: 5354556 (1994-10-01), Sparks et al.
patent: 5407609 (1995-04-01), Tice et al.
patent: 5453425 (1995-09-01), Francois et al.
patent: 5478564 (1995-12-01), Wantier et al.
patent: 5503851 (1996-04-01), Mank et al.
patent: 5585460 (1996-12-01), Yamada et al.
patent: 5650173 (1997-07-01), Ramstack et al.
patent: 5656299 (1997-08-01), Kino et al.
patent: 5759563 (1998-06-01), Yewey et al.
patent: 5770231 (1998-06-01), Mesens et al.
patent: 5792477 (1998-08-01), Rickey et al.
patent: 5851451 (1998-12-01), Takechi et al.
patent: 5919408 (1999-07-01), Muller et al.
patent: 6045830 (2000-04-01), Igari et al.
patent: 6080429 (2000-06-01), Cleland et al.
patent: 6224794 (2001-05-01), Amsden et al.
patent: 0 052 510 (1982-05-01), None
patent: 0 071 454 (1983-02-01), None
patent: 0 129 619 (1985-01-01), None
patent: 0 195 450 (1986-09-01), None
patent: 0 196 132 (1986-10-01), None
patent: 0 248 531 (1987-12-01), None
patent: 0 266 119 (1988-05-01), None
patent: 0368 388 (1990-05-01), None
patent: 0 486 959 (1992-05-01), None
patent: 0 452 111 (1998-07-01), None
patent: 0 605 933 (1998-10-01), None
patent: 0 724 433 (1998-12-01), None
patent: 0 709 085 (2001-01-01), None
patent: 0 761 213 (2002-10-01), None
patent: 1 214 058 (2003-07-01), None
patent: 1 033 973 (2003-09-01), None
patent: 0 975 334 (2003-10-01), None
patent: 1 345 979 (2004-07-01), None
patent: 1 212 730 (1970-11-01), None
patent: 1 351 811 (1974-03-01), None
patent: 2 015 360 (1979-09-01), None
patent: 2 120 113 (1983-11-01), None
patent: 2 246 573 (1992-02-01), None
patent: WO 88/01165 (1988-02-01), None
patent: WO 90/13361 (1990-11-01), None
patent: 91/13595 (1991-09-01), None
patent: WO 91/17772 (1991-11-01), None
patent: WO 94/10982 (1994-07-01), None
patent: WO 94/25460 (1994-11-01), None
patent: WO 95/13799 (1995-05-01), None
Bodmeier, R. et al., Solvent selection in the preparation of poly(DL-lactide) microspheres prepared by the solvent evaporation method, International Journal of Pharmaceutica, 43:179-186 (1988).
Fong, J. W. et al., Enhancing Drug Release from Polylactide Microspheres by Using Base in the Microencapsulation Process, American Chemical Society, Chapter 16, 214-230 (1987).
Herrling, P.L., Mechanism of Action of Atypical Antipsychotics, Pharmacopsychiat., 24:48-49 (1991).
Suzuki, K. et al., Microencapsulation and Dissolution Properties of a Neuroleptic in a Biodegradable Polymer, Poly(d,I-lactide), Journal of Pharmaceutical Sciences, 74(1):21-24 (1985).
Abstract of WO 94/10982, Kino et al., “Sustained-release Microspheres Requiring No Surgical Implant—Contains Hydriophobic Antipsychotic Encapsulated in Biodegradable Polymer, Allowing Prolonged Therapeutic Effect by Infrequent Administration,” (Jul. 1994).
Baker, J.R., “Motionless Mixers Stir Up New Uses,”Chemical Engineering Progress: 32-38 (Jun. 1991).
Borison, R.L. et al., Clinical Overview of Risperidone, in: Meltzer, H., Y., ed.,Novel Antipsychotic Drugs, Raven Press, Ltd., N.Y.: 233-239 (1992).
Chang, R. et al., “Dissolution Characterization of Polycaproláctone-Polylactide Microspheres of Chlorpromazine,”Drug Development and Industrial Pharmacy, vol. 12, No. 14, 2355-2380 (1986).
Chemineer, “Kenics Static Mixers,”Bulletin800: 1-11 (1986).
Chouinard, G. et al., “A Canadian Multicenter Placebo-Controlled Study of Fixed Doses of Risperidone and Haloperiodol in the Treatment of Chronic Schizophrenic Patients,”Journal of Clinical Psychopharmacology, vol. 13, No. 1, 25-40 (1993).
Glazer, W.M. et al., “Depot Neuroleptic Therapy: An Underutilized Treatment Option,”J. Clin Psychiatry53 (12):426-433 (Dec. 1992).
Heinrich, K. et al., “Experimental Comparison of the Efficacy and Compatibility of Risperidone and Clozapine in Acute Schizophrenia,” in: Kane, J.M. (ed), Risperidone: Major Progress in Antipsychotic Treatment.Oxford Clinical Communications. Oxford: 37-39 (1991).
Janssen and Niernegeers, “Chemistry and pharmacology of compounds related to 4-(4-hydroxy-4-phenyl-piperidino)-butyrophenone,”Arzneim.-Forsch. (Drug Res.) 12:765-767 (1959).
Janssen, P.A.J. et al., “Is it Possible to Predict the Clinical Effects of Neuroleptic Drugs (Major Tranquilizers) from Animal Data?,”Arzneimit. Forsch. (Drug Res.) 10:1196-1206 (1965).
Janssen, P.A.J. et al., “Pharmacology of Risperidone (R 64 766), a New Antipsychotic With Serotonin—S2and Dopamine—D2Antagonistic Properties,”The Journal of Pharmacology and Experimental Therapeutics, vol. 244, No. 2, 685-693 (1988).
Koch Engineering Company Inc., “All Mixing Problems Are Not Alike,” 1 page,Product BrochureNo date available.
Koch Engineering Company Inc., “Static Mixing Technology,” Article: 1-15 (1991).
Koflo Corporation, “Static In-Line Mixers,” 4 pages,Product Brochure no date available.
Kormax Systems, Inc., “Triple Action Static Mixers,” 2 pages,Product Brochure no date available.
Leysen, J.E., et al., “Biochemical Profile of Risperidone, a New Antipsychotic,”The Journal of Pharmacology and Experimental Therapeutics, vol. 247, No. 2, 661-670 (1988).
Leyson, J.E. et al., “In vitroreceptor binding and neurotransmitter uptake inhibition profile of

Affiliated with

Also associated with

Rating

Microencapsulated 3-piperidinyl-substituted... does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Microencapsulated 3-piperidinyl-substituted..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Microencapsulated 3-piperidinyl-substituted... will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-3699923